BGM vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score and negative profitability metrics raise concerns. The company is unprofitable with a -26.32% profit margin, -5.41% operating margin, and negative ROE and ROA, while revenue has collapsed by 56.90% year-over-year. Valuation multiples are extremely high with a Price/Sales ratio of 24.99 despite deteriorating fundamentals, and the stock has lost 90.8% of its value over five years. Although the balance sheet shows no debt and strong liquidity ratios, the lack of earnings, cash flow data, and analyst coverage suggests high uncertainty and limited investor confidence.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BGM vs MRK: Head-to-Head Comparison
This page compares BGM Group Ltd. (BGM) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.